In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease.

25.01.2018

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue